Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhibitors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback